Better Therapeutics, a prescription digital therapeutics company, went public via a SPAC merger with Mountain Crest Acquisition in a $187m deal. The PIPE was led by Farallon Capital Management, RS Investments, Sectoral Asset Management, and Monashee Investment Management, with participation from other undisclosed investors. “This is a unique time to build a company like Better Therapeutics. Patients, doctors and insurers have grown increasingly comfortable with digitally delivered solutions, including prescription digital therapeutics, and we are uniquely positioned to change the way some of the most prevalent and costly diseases are treated,” Kevin Appelbaum, Better Therapeutics Co-founder and Chief Executive Officer.